“We really appreciate what you did for our study. A new assay development was successful. The study report was well-documented.”
Recent News
- iLEADS BMS presents the effects of its novel FXR agonist in Physiogenex’s ALD/MetALD hamster models at APASL 2024, Kyoto, Japan 03/03/2024
- HepaRegenix publishes data on first in class MKK4 inhibitors demonstrating benefits in Physiogenex CCl4 mouse model of liver fibrosis 01/30/2024
- iLeads BMS publishes a new manuscript about its novel FXR agonist in Physiogenex’s obese MASH hamster and mouse models 12/04/2023
- Physiogenex to present its obese MetALD hamster model at the 7th Obesity and NASH Summit in Boston, MA, Nov. 27-29, 2023 11/23/2023
- Physiogenex to present its novel obese hamster model of MetALD at the AASLD Liver Meeting 2023 in Boston, Nov. 10-14 11/06/2023
- Physiogenex to present at the 7th IPF Summit in Boston, MA, Sept. 19-21, 2023 11/06/2023